Unternehmen wird geladen
Just reported
Q3 2026 results
From Sutro Biopharma's results release of 12. November 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
9,1M $
-6,1 % y/y
-7,5 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
-22M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Sutro Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B $A+
EXELExelixis, Inc.17B $A+
JAZZJazz Pharmaceuticals plc15,4B $A
HALOHalozyme Therapeutics, Inc.11,5B $A+
TECHBIO-Techne Corp11,4B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now A
Gebaut aus den eigenen Einreichungen von Sutro Biopharma, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
